About us
Empowering the future of medicine by integrating artificial intelligence and multiomics.
Our Technology
Our Technology
MAT a one-of-a-kind platform, is transforming medicine and technology alike. Uniquely designed from the ground up, it is the future of predictive healthcare, merging advanced neural networks and machine learning to simulate human systems biology.
This isn't just a mere evolution in technology, it's the birth of a new era.
MAT a one-of-a-kind platform, is transforming medicine and technology alike. Uniquely designed from the ground up, it is the future of predictive healthcare, merging advanced neural networks and machine learning to simulate human systems biology.
This isn't just a mere evolution in technology, it's the birth of a new era.
Our Expert Team
Our Expert Team
The Minds Behind the Innovation
The Minds Behind the Innovation
Meet the remarkable team steering GATC Health into the future. Our leadership is comprised of seasoned professionals from technology, science, and finance sectors.
Meet the remarkable team steering GATC Health into the future. Our leadership is comprised of seasoned professionals from technology, science, and finance sectors.
John Stroh
Chief Executive Officer
READ BIO
John Stroh
Chief Executive Officer
READ BIO
Jayson Uffens
Chief Technology Officer
READ BIO
Jayson Uffens
Chief Technology Officer
READ BIO
Jeff Moses
President
READ BIO
Jeff Moses
President
READ BIO
Ian Jenkins
Chief Science Officer
READ BIO
Ian Jenkins
Chief Science Officer
READ BIO
Tyrone Lam
Chief Business Officer
READ BIO
Tyrone Lam
Chief Business Officer
READ BIO
Vaishnavi Narayan
Principal AI Engineer
READ BIO
Vaishnavi Narayan
Principal AI Engineer
READ BIO
Eric J. Mathur
Chief Innovation Officer
READ BIO
Eric J. Mathur
Chief Innovation Officer
READ BIO
Gene O’Bryan
Chief Operating Officer
READ BIO
Gene O’Bryan
Chief Operating Officer
READ BIO
Jonathan Lakey, PhD, MSM
Chair of Scientific Advisory Board
READ BIO
Jonathan Lakey, PhD, MSM
Chair of Scientific Advisory Board
READ BIO
Michael Manahan
Chief Financial Officer
READ BIO
Michael Manahan
Chief Financial Officer
READ BIO
Waldemar Lernhardt, PhD
Vice President Scientific Operations
READ BIO
Waldemar Lernhardt, PhD
Vice President Scientific Operations
READ BIO
Robert Tinder, PhD
Head of Chemical Research
READ BIO
Robert Tinder, PhD
Head of Chemical Research
READ BIO
Saman Mirzaei, PhD
Senior Scientist
READ BIO
Saman Mirzaei, PhD
Senior Scientist
READ BIO
John Stroh
Chief Executive Officer
READ BIO
John Stroh
Chief Executive Officer
READ BIO
Jayson Uffens
Chief Technology Officer
READ BIO
Jayson Uffens
Chief Technology Officer
READ BIO
Ian Jenkins
Chief Science Officer
READ BIO
Ian Jenkins
Chief Science Officer
READ BIO
Jeff Moses
President
READ BIO
Jeff Moses
President
READ BIO
Robert Sorrentino, MD
Chief Medical Officer
READ BIO
Vaishnavi Narayan
Principle AI Engineer
READ BIO
Vaishnavi Narayan
Principle AI Engineer
READ BIO
Tyrone Lam
Chief Business Officer
READ BIO
Tyrone Lam
Chief Business Officer
READ BIO
Michael Manahan
Chief Financial Officer
READ BIO
Michael Manahan
Chief Financial Officer
READ BIO
Eric J. Mathur
Chief Innovation Officer
READ BIO
Eric J. Mathur
Chief Innovation Officer
READ BIO
Jonathan Lakey, PhD, MSM
Chair of Scientific Advisory Board
READ BIO
Jonathan Lakey, PhD, MSM
Chair of Scientific Advisory Board
READ BIO
Waldemar Lernhardt, PhD
Vice President Scientific Operations
READ BIO
Waldemar Lernhardt, PhD
Vice President Scientific Operations
READ BIO
Gene O’Bryan
Chief Operating Officer
READ BIO
Gene O’Bryan
Chief Operating Officer
READ BIO
Saman Mirzaei, PhD
Senior Scientist
READ BIO
Saman Mirzaei, PhD
Senior Scientist
READ BIO
Robert Tinder, PhD
Head of Chemical Research
READ BIO
Robert Tinder, PhD
Head of Chemical Research
READ BIO
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stake-holders in the healthcare community.
Tomas Philipson, PhD
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stake-holders in the healthcare community.
Tomas Philipson, PhD
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stake-holders in the healthcare community.
Tomas Philipson, PhD
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stake-holders in the healthcare community.
Tomas Philipson, PhD
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Herb Boyer
Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion
I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.
Patrick Lilley
CEO of Liquid Biosciences
What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.
Lin Yu, PhD
Former Managing Director Healthcare Investment Banking, Oppenheimer
I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.
Tomas Philipson
Former Acting Chairman of the White House Council of Economic Advisers
I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.
Mark Palaima
Former Chief Architect at eBay
This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.
Guiding Us Toward Excellence
Guiding Us Toward Excellence
Our Advisors and Mentors
Our Advisors and Mentors
Our board of advisors is a powerhouse of knowledge and experience. Comprising esteemed researchers, medical doctors, biotech executives, and policy experts, they offer invaluable guidance in steering GATC's mission.
Our board of advisors is a powerhouse of knowledge and experience. Comprising esteemed researchers, medical doctors, biotech executives, and policy experts, they offer invaluable guidance in steering GATC's mission.
Tomas Philipson, PhD
Health Policy and Pharma Advisor
READ BIO
Former Acting Chairman of the Council of Economic Advisers in the Trump administration
Former senior economic advisor to the head of the Food and Drug Association
Former senior economic advisor to the head of the Centers for Medicare & Medicaid Services
Professor of Public Policy Studies Emeritus at the Univ of Chicago Harris School of Public Policy
Chad Beyer, PhD
Science Advisor
READ BIO
25 years of CNS drug discovery and development experience
33 INDs; 70+ manuscripts; 2 blockbuster medications
NIDA; Wyeth; Ariel and Promentis Pharmaceuticals
John O'Reilly
Health Policy Advisor
READ BIO
Leader in healthcare, law, and business advisory.
Chairs UCLA Health System Board and University Medical Center of Southern Nevada.
Extensive experience in healthcare innovation and strategic planning.
Cum laude graduate in law and accounting, ex-military legal officer.
Dr. Jack Lewin
Medical Advisor
READ BIO
Administrator, Hawaii State Health Planning Development, Sr Advisor to Governor
Former CEO, American College of Cardiology, California Medical Assoc
Former President & CEO of Cardiovascular Research Foundation
Dr. Seema Gupta
Medical Advisor
READ BIO
Primary Care Physician with Veterans Administration (20 years).
Expert in Internal Medicine, Preventive Medicine, Public Health, Global Health.
Editorial Board of Internal Medicine Alerts (leading publication for medical providers).
Patrick Lilley
Science Advisor
READ BIO
CEO and Founder, Liquid Biosciences
Member Blockchain & AI Task Force
Inventor 75+ patents & trade secrets
Board Member, Mamogen, HepGene, LiquidLung
Mark Palaima
Technology Advisor
READ BIO
eBay—Chief Architect, Fellow—10 yrs.
Inkiru, Inc (Acquired by Walmart Labs)—Chief Scientist, Founder
Ismintis Systems —Founder
Dr. Stanley Lewis
Medical Advisor
READ BIO
Co-founder & CEO, A28 Therapeutics
Former Chief Medical Officer, Ansun Biopharma
Former Chief Medical Officer, TaliMed Biologics
Gerald P. Curatola, D.D.S.
Business Development Advisor
READ BIO
Internationally recognized biological doctor, inventor, author, and wellness pioneer
Adj. Clinical Associate Professor, New York University College of Dentistry
Founder of Rejuvenation Health, medical and dental practices, and Revitin Oral Care.
Dr. David Kushner
Nuclear Radiology Specialist
READ BIO
35+ years as Nuclear Radiology Specialist / US Navy Physician
Fellow in Musculoskeletal imaging and Nuclear Medicine
Assistant professor at Uniform University of the Health Science
Herbert Boyer
Science Advisor
READ BIO
Co-founder Genentech (first biotech company to go public)
Co-discovered methods that founded genetic engineering.
Numerous awards including the Albert Lasker Award for Medical Research, Industrial Research Institute Achievement Award, the National Medal of Technology, National Medal of Science.
Richard Schatz, MD
Chair of Medical Advisor Board
READ BIO
Co-inventor of the coronary stent and international expert in interventional cardiology
Inducted into the National Academy of Inventors and won the prestigious Russ Prize for Bioengineering, considered the American Nobel Prize
Adjunct Professor of Medicine and Cardiology at Duke University
Lin Yu, PhD
Board of Directors
READ BIO
Former Managing Director Oppenheimer Healthcare Investment Banking
Former Managing Director at BTIG Healthcare Investment Banking
Ph.D. from Columbia University in chemical engineering focused on next-generation DNA sequencing technologies
Joseph Stauffer
Medical Advisor
READ BIO
CEO/Founder Alta Life Sciences, CMO Antibe Therapeutics, Chairman BioFuse Medical Technologies
Former Assistant Professor John Hopkins Medicine, FDA Medical Officer, Global Medical Director for Abbott Labs, U.S. Navy Medical.
Jayson Hymes
Medical Advisor
READ BIO
Fellow of the American College of Pain Medicine, Fellow of the American Society of Addiction Medicine, Assistant Clinical Professor Anesthesiology & Pain Medicine at USC School of Medicine
Former advisor to Office of National Drug Control Policy, the Medical Board of California, California Narcotics Officers Association, Los Angeles Field Division of the DEA.
Tomas Philipson, PhD
Health Policy and Pharma Advisor
READ BIO
Former Acting Chairman of the Council of Economic Advisers in the Trump administration
Former senior economic advisor to the head of the Food and Drug Association
Former senior economic advisor to the head of the Centers for Medicare & Medicaid Services
Professor of Public Policy Studies Emeritus at the Univ of Chicago Harris School of Public Policy
Chad Beyer, PhD
Science Advisor
READ BIO
25 years of CNS drug discovery and development experience
33 INDs; 70+ manuscripts; 2 blockbuster medications
NIDA; Wyeth; Ariel and Promentis Pharmaceuticals
John O'Reilly
Health Policy Advisor
READ BIO
Leader in healthcare, law, and business advisory.
Chairs UCLA Health System Board and University Medical Center of Southern Nevada.
Extensive experience in healthcare innovation and strategic planning.
Cum laude graduate in law and accounting, ex-military legal officer.
Dr. Jack Lewin
Medical Advisor
READ BIO
Administrator, Hawaii State Health Planning Development, Sr Advisor to Governor
Former CEO, American College of Cardiology, California Medical Assoc
Former President & CEO of Cardiovascular Research Foundation
Dr. Seema Gupta
Medical Advisor
READ BIO
Primary Care Physician with Veterans Administration (20 years).
Expert in Internal Medicine, Preventive Medicine, Public Health, Global Health.
Editorial Board of Internal Medicine Alerts (leading publication for medical providers).
Patrick Lilley
Science Advisor
READ BIO
CEO and Founder, Liquid Biosciences
Member Blockchain & AI Task Force
Inventor 75+ patents & trade secrets
Board Member, Mamogen, HepGene, LiquidLung
Mark Palaima
Technology Advisor
READ BIO
eBay—Chief Architect, Fellow—10 yrs.
Inkiru, Inc (Acquired by Walmart Labs)—Chief Scientist, Founder
Ismintis Systems —Founder
Dr. Stanley Lewis
Medical Advisor
READ BIO
Co-founder & CEO, A28 Therapeutics
Former Chief Medical Officer, Ansun Biopharma
Former Chief Medical Officer, TaliMed Biologics
Gerald P. Curatola, D.D.S.
Business Development Advisor
READ BIO
Internationally recognized biological doctor, inventor, author, and wellness pioneer
Adj. Clinical Associate Professor, New York University College of Dentistry
Founder of Rejuvenation Health, medical and dental practices, and Revitin Oral Care.
Dr. David Kushner
Nuclear Radiology Specialist
READ BIO
35+ years as Nuclear Radiology Specialist / US Navy Physician
Fellow in Musculoskeletal imaging and Nuclear Medicine
Assistant professor at Uniform University of the Health Science
Herbert Boyer
Science Advisor
READ BIO
Co-founder Genentech (first biotech company to go public)
Co-discovered methods that founded genetic engineering.
Numerous awards including the Albert Lasker Award for Medical Research, Industrial Research Institute Achievement Award, the National Medal of Technology, National Medal of Science.
Richard Schatz, MD
Chair of Medical Advisor Board
READ BIO
Co-inventor of the coronary stent and international expert in interventional cardiology
Inducted into the National Academy of Inventors and won the prestigious Russ Prize for Bioengineering, considered the American Nobel Prize
Adjunct Professor of Medicine and Cardiology at Duke University
Lin Yu, PhD
Board of Directors
READ BIO
Former Managing Director Oppenheimer Healthcare Investment Banking
Former Managing Director at BTIG Healthcare Investment Banking
Ph.D. from Columbia University in chemical engineering focused on next-generation DNA sequencing technologies
Joseph Stauffer
Medical Advisor
READ BIO
CEO/Founder Alta Life Sciences, CMO Antibe Therapeutics, Chairman BioFuse Medical Technologies
Former Assistant Professor John Hopkins Medicine, FDA Medical Officer, Global Medical Director for Abbott Labs, U.S. Navy Medical.
Jayson Hymes
Medical Advisor
READ BIO
Fellow of the American College of Pain Medicine, Fellow of the American Society of Addiction Medicine, Assistant Clinical Professor Anesthesiology & Pain Medicine at USC School of Medicine
Former advisor to Office of National Drug Control Policy, the Medical Board of California, California Narcotics Officers Association, Los Angeles Field Division of the DEA.
Tomas Philipson, PhD
Health Policy and Pharma Advisor
READ BIO
Former Acting Chairman of the Council of Economic Advisers in the Trump administration
Former senior economic advisor to the head of the Food and Drug Association
Former senior economic advisor to the head of the Centers for Medicare & Medicaid Services
Professor of Public Policy Studies Emeritus at the Univ of Chicago Harris School of Public Policy
Chad Beyer, PhD
Science Advisor
READ BIO
25 years of CNS drug discovery and development experience
33 INDs; 70+ manuscripts; 2 blockbuster medications
NIDA; Wyeth; Ariel and Promentis Pharmaceuticals
John O'Reilly
Health Policy Advisor
READ BIO
Leader in healthcare, law, and business advisory.
Chairs UCLA Health System Board and University Medical Center of Southern Nevada.
Extensive experience in healthcare innovation and strategic planning.
Cum laude graduate in law and accounting, ex-military legal officer.
Dr. Jack Lewin
Medical Advisor
READ BIO
Administrator, Hawaii State Health Planning Development, Sr Advisor to Governor
Former CEO, American College of Cardiology, California Medical Assoc
Former President & CEO of Cardiovascular Research Foundation
Dr. Seema Gupta
Medical Advisor
READ BIO
Primary Care Physician with Veterans Administration (20 years).
Expert in Internal Medicine, Preventive Medicine, Public Health, Global Health.
Editorial Board of Internal Medicine Alerts (leading publication for medical providers).
Patrick Lilley
Science Advisor
READ BIO
CEO and Founder, Liquid Biosciences
Member Blockchain & AI Task Force
Inventor 75+ patents & trade secrets
Board Member, Mamogen, HepGene, LiquidLung
Mark Palaima
Technology Advisor
READ BIO
eBay—Chief Architect, Fellow—10 yrs.
Inkiru, Inc (Acquired by Walmart Labs)—Chief Scientist, Founder
Ismintis Systems —Founder
Dr. Stanley Lewis
Medical Advisor
READ BIO
Co-founder & CEO, A28 Therapeutics
Former Chief Medical Officer, Ansun Biopharma
Former Chief Medical Officer, TaliMed Biologics
Gerald P. Curatola, D.D.S.
Business Development Advisor
READ BIO
Internationally recognized biological doctor, inventor, author, and wellness pioneer
Adj. Clinical Associate Professor, New York University College of Dentistry
Founder of Rejuvenation Health, medical and dental practices, and Revitin Oral Care.
Dr. David Kushner
Nuclear Radiology Specialist
READ BIO
35+ years as Nuclear Radiology Specialist / US Navy Physician
Fellow in Musculoskeletal imaging and Nuclear Medicine
Assistant professor at Uniform University of the Health Science
Herbert Boyer
Science Advisor
READ BIO
Co-founder Genentech (first biotech company to go public)
Co-discovered methods that founded genetic engineering.
Numerous awards including the Albert Lasker Award for Medical Research, Industrial Research Institute Achievement Award, the National Medal of Technology, National Medal of Science.
Richard Schatz, MD
Chair of Medical Advisor Board
READ BIO
Co-inventor of the coronary stent and international expert in interventional cardiology
Inducted into the National Academy of Inventors and won the prestigious Russ Prize for Bioengineering, considered the American Nobel Prize
Adjunct Professor of Medicine and Cardiology at Duke University
Lin Yu, PhD
Board of Directors
READ BIO
Former Managing Director Oppenheimer Healthcare Investment Banking
Former Managing Director at BTIG Healthcare Investment Banking
Ph.D. from Columbia University in chemical engineering focused on next-generation DNA sequencing technologies
Joseph Stauffer
Medical Advisor
READ BIO
CEO/Founder Alta Life Sciences, CMO Antibe Therapeutics, Chairman BioFuse Medical Technologies
Former Assistant Professor John Hopkins Medicine, FDA Medical Officer, Global Medical Director for Abbott Labs, U.S. Navy Medical.
Jayson Hymes
Medical Advisor
READ BIO
Fellow of the American College of Pain Medicine, Fellow of the American Society of Addiction Medicine, Assistant Clinical Professor Anesthesiology & Pain Medicine at USC School of Medicine
Former advisor to Office of National Drug Control Policy, the Medical Board of California, California Narcotics Officers Association, Los Angeles Field Division of the DEA.
Tomas Philipson, PhD
Health Policy and Pharma Advisor
READ BIO
Former Acting Chairman of the Council of Economic Advisers in the Trump administration
Former senior economic advisor to the head of the Food and Drug Association
Former senior economic advisor to the head of the Centers for Medicare & Medicaid Services
Professor of Public Policy Studies Emeritus at the Univ of Chicago Harris School of Public Policy
Chad Beyer, PhD
Science Advisor
READ BIO
25 years of CNS drug discovery and development experience
33 INDs; 70+ manuscripts; 2 blockbuster medications
NIDA; Wyeth; Ariel and Promentis Pharmaceuticals
John O'Reilly
Health Policy Advisor
READ BIO
Leader in healthcare, law, and business advisory.
Chairs UCLA Health System Board and University Medical Center of Southern Nevada.
Extensive experience in healthcare innovation and strategic planning.
Cum laude graduate in law and accounting, ex-military legal officer.
Dr. Jack Lewin
Medical Advisor
READ BIO
Administrator, Hawaii State Health Planning Development, Sr Advisor to Governor
Former CEO, American College of Cardiology, California Medical Assoc
Former President & CEO of Cardiovascular Research Foundation
Dr. Seema Gupta
Medical Advisor
READ BIO
Primary Care Physician with Veterans Administration (20 years).
Expert in Internal Medicine, Preventive Medicine, Public Health, Global Health.
Editorial Board of Internal Medicine Alerts (leading publication for medical providers).
Patrick Lilley
Science Advisor
READ BIO
CEO and Founder, Liquid Biosciences
Member Blockchain & AI Task Force
Inventor 75+ patents & trade secrets
Board Member, Mamogen, HepGene, LiquidLung
Mark Palaima
Technology Advisor
READ BIO
eBay—Chief Architect, Fellow—10 yrs.
Inkiru, Inc (Acquired by Walmart Labs)—Chief Scientist, Founder
Ismintis Systems —Founder
Dr. Stanley Lewis
Medical Advisor
READ BIO
Co-founder & CEO, A28 Therapeutics
Former Chief Medical Officer, Ansun Biopharma
Former Chief Medical Officer, TaliMed Biologics
Gerald P. Curatola, D.D.S.
Business Development Advisor
READ BIO
Internationally recognized biological doctor, inventor, author, and wellness pioneer
Adj. Clinical Associate Professor, New York University College of Dentistry
Founder of Rejuvenation Health, medical and dental practices, and Revitin Oral Care.
Dr. David Kushner
Nuclear Radiology Specialist
READ BIO
35+ years as Nuclear Radiology Specialist / US Navy Physician
Fellow in Musculoskeletal imaging and Nuclear Medicine
Assistant professor at Uniform University of the Health Science
Herbert Boyer
Science Advisor
READ BIO
Co-founder Genentech (first biotech company to go public)
Co-discovered methods that founded genetic engineering.
Numerous awards including the Albert Lasker Award for Medical Research, Industrial Research Institute Achievement Award, the National Medal of Technology, National Medal of Science.
Richard Schatz, MD
Chair of Medical Advisor Board
READ BIO
Co-inventor of the coronary stent and international expert in interventional cardiology
Inducted into the National Academy of Inventors and won the prestigious Russ Prize for Bioengineering, considered the American Nobel Prize
Adjunct Professor of Medicine and Cardiology at Duke University
Lin Yu, PhD
Board of Directors
READ BIO
Former Managing Director Oppenheimer Healthcare Investment Banking
Former Managing Director at BTIG Healthcare Investment Banking
Ph.D. from Columbia University in chemical engineering focused on next-generation DNA sequencing technologies
Joseph Stauffer
Medical Advisor
READ BIO
CEO/Founder Alta Life Sciences, CMO Antibe Therapeutics, Chairman BioFuse Medical Technologies
Former Assistant Professor John Hopkins Medicine, FDA Medical Officer, Global Medical Director for Abbott Labs, U.S. Navy Medical.
Jayson Hymes
Medical Advisor
READ BIO
Fellow of the American College of Pain Medicine, Fellow of the American Society of Addiction Medicine, Assistant Clinical Professor Anesthesiology & Pain Medicine at USC School of Medicine
Former advisor to Office of National Drug Control Policy, the Medical Board of California, California Narcotics Officers Association, Los Angeles Field Division of the DEA.
Tomas Philipson, PhD
Health Policy and Pharma Advisor
READ BIO
Former Acting Chairman of the Council of Economic Advisers in the Trump administration
Former senior economic advisor to the head of the Food and Drug Association
Former senior economic advisor to the head of the Centers for Medicare & Medicaid Services
Professor of Public Policy Studies Emeritus at the Univ of Chicago Harris School of Public Policy
Chad Beyer, PhD
Science Advisor
READ BIO
25 years of CNS drug discovery and development experience
33 INDs; 70+ manuscripts; 2 blockbuster medications
NIDA; Wyeth; Ariel and Promentis Pharmaceuticals
John O'Reilly
Health Policy Advisor
READ BIO
Leader in healthcare, law, and business advisory.
Chairs UCLA Health System Board and University Medical Center of Southern Nevada.
Extensive experience in healthcare innovation and strategic planning.
Cum laude graduate in law and accounting, ex-military legal officer.
Dr. Jack Lewin
Medical Advisor
READ BIO
Administrator, Hawaii State Health Planning Development, Sr Advisor to Governor
Former CEO, American College of Cardiology, California Medical Assoc
Former President & CEO of Cardiovascular Research Foundation